OncoMatch/Clinical Trials/NCT06196255
Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Is NCT06196255 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies anti-FcRL5 CAR-T for multiple myeloma.
Treatment: anti-FcRL5 CAR-T — This is an open label, single-arm, Phase 2 study to evaluate the efficacy and safety of Anti-FcRL5 CAR-T in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture. Anti-FcRL5 chimeric antigen receptor (CAR) modified T cells. Prior to Anti-FcRL5 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Demographics
Lab requirements
Kidney function
no serious kidney disease
Liver function
ALT and AST <3 times normal; bilirubin <2.0mg / dl
Cardiac function
no serious heart disease
ALT and AST <3 times normal; bilirubin <2.0mg / dl; The patient has no serious heart, liver, kidney and other diseases
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06196255 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages